Neuroscience On Barriers In Development (NEUROBID)
Funder
National Health and Medical Research Council
Funding Amount
$600,927.00
Summary
The program aims to understand normal and disturbed brain barrier function in development to devise ways of preventing or ameliorating neurological conditions in infants or adult neurological disorders with developmental origins. Unique features of transport mechanisms across brain barriers will be used to design novel methods of targeting therapeutic macromolecular and cellular agents to the brain barriers and transporting them into brain for treatment of neurological diseases in young and old.
Assessment To Service Outcomes - Care Pathways For Older Australians With Dementia, CVD And Arthritis
Funder
National Health and Medical Research Council
Funding Amount
$656,029.00
Summary
The project aims to use existing data source to answer questions similar to �What happens to people after they have been assessed and recommended for aged care? in respect of service delivery for people with one of the three chronic conditions dementia, arthritis or cardiovascular disease. The project is to provide information about issues such as �bed blockers� and determine if the outcomes are different for people who have been assessed for aged care while they are in hospital. It is to chart ....The project aims to use existing data source to answer questions similar to �What happens to people after they have been assessed and recommended for aged care? in respect of service delivery for people with one of the three chronic conditions dementia, arthritis or cardiovascular disease. The project is to provide information about issues such as �bed blockers� and determine if the outcomes are different for people who have been assessed for aged care while they are in hospital. It is to chart changes in service use over time and examine factors that affect the type of care used by older people.Read moreRead less
Early Intervention To Prevent Childhood Obesity Among A Disadvantaged Population: A Home-based Randomised Controlled Tri
Funder
National Health and Medical Research Council
Funding Amount
$675,082.00
Summary
This intervention research will conduct a randomised controlled trial, of a community-based early childhood home visiting intervention designed to improve family and behavioural risk factors for childhood obesity and overweight. This intervention which will be developed in collaboration with the Health Promotion Unit, Child and Family Health Nurses, university academic experts and mothers in the community promises to deliver significant health and social benefits, in particular, preventing early ....This intervention research will conduct a randomised controlled trial, of a community-based early childhood home visiting intervention designed to improve family and behavioural risk factors for childhood obesity and overweight. This intervention which will be developed in collaboration with the Health Promotion Unit, Child and Family Health Nurses, university academic experts and mothers in the community promises to deliver significant health and social benefits, in particular, preventing early onset of childhood obesity. It will result in a series of recommendations for policies and practical methods for promoting healthy feeding and physical activity of infants under two years of age with particular application to families who are socially and economically disadvantaged. These policies and practical methods for preventing childhood obesity could be used across Australia.Read moreRead less
Chimeric Virus-like Particles (VLPs) Displaying H1, H3 And H5 Haemagglutinins - Construction And Immunogenicity
Funder
National Health and Medical Research Council
Funding Amount
$207,543.00
Summary
Virus-like particles (VLPs) provoke strong immune responses in the body. We have developed a novel VLP system that allows the production of VLPs containing foreign vaccine antigens of much larger size than previously possible, and have shown that these VLPs provoke strong immune responses in mice without the use of adjuvants. The capacity of these VLPs is large enough to accommodate the most important vaccine antigen of influenza, the haemagglutinin (HA) molecule. We will test whether VLPs can b ....Virus-like particles (VLPs) provoke strong immune responses in the body. We have developed a novel VLP system that allows the production of VLPs containing foreign vaccine antigens of much larger size than previously possible, and have shown that these VLPs provoke strong immune responses in mice without the use of adjuvants. The capacity of these VLPs is large enough to accommodate the most important vaccine antigen of influenza, the haemagglutinin (HA) molecule. We will test whether VLPs can be produced containing each of the three most important HA types _ H1 and H3 that are currently circulating in man, and H5 (avian) that is considered a pandemic threat. VLPs will be tested for their ability to induce neutralizing antibody and cellular immune responses in mice, and for their ability to protect ferrets from influenza infection. If successful, the HA-VLP system would provide a method for the rapid production of new influenza vaccines using large-scale fermentation technology as for hepatitis B and many other vaccines, rather than eggs or cell culture as used for current influenza vaccines.Read moreRead less
Retroviral Expression Cloning Using An Arrayed Full Length CDNA Gene Set
Funder
National Health and Medical Research Council
Funding Amount
$1,841,500.00
Summary
The sequencing of the human genome has revealed the blueprint for life, but the identities and-or functions of the majority of genes remain unknown. Here we propose to establish a radically modified retroviral expression cloning system that will, in principle, allow identification of all genes that confer a particular dominant phenotype. To do this we will establish an arrayed retroviral library of sequence-verified genes covering the entire human transcriptome. This technology will be used to i ....The sequencing of the human genome has revealed the blueprint for life, but the identities and-or functions of the majority of genes remain unknown. Here we propose to establish a radically modified retroviral expression cloning system that will, in principle, allow identification of all genes that confer a particular dominant phenotype. To do this we will establish an arrayed retroviral library of sequence-verified genes covering the entire human transcriptome. This technology will be used to identify genes involved in a wide range of medically-important biological processes.Read moreRead less
Assessment Of Alpha-galactosylceramide As A Novel Adjuvant For Pandemic Influenza: A Virua Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$220,042.00
Summary
The occurrence of human infections with pathogenic avian H5N1 Influenza A viruses was the first documentation of these viruses demonstrating an ability to directly transmit from birds to humans. The virulent nature of these infections, and the fact that there is no pre-existing immunity to these viruses in the human population has raised the concern that these viruses may emerge to cause the next influenza pandemic. Vaccination is our most effective way of protecting against influenza infection, ....The occurrence of human infections with pathogenic avian H5N1 Influenza A viruses was the first documentation of these viruses demonstrating an ability to directly transmit from birds to humans. The virulent nature of these infections, and the fact that there is no pre-existing immunity to these viruses in the human population has raised the concern that these viruses may emerge to cause the next influenza pandemic. Vaccination is our most effective way of protecting against influenza infection, however there are no commercially available avian influenza vaccines available. Moreover, recent evidence suggests current vaccines strategies may be less than effective. This proposal aims to evaluate the efficacy of a novel vaccine strategy that promotes immune protection against a potential pandemic influenza strain.Read moreRead less
They aim to create insulin-secreting B cells by identifying their progenitor cells and the moleculaes normally required for their development, in order to restore B-cell function in the people with type 1 diabetes. Mouse and human multipotent embryonic stem (ES) cells and fetal mouse panceas and adult pancreas duct cells will be used as sources of progenitor B cells. Comparative studies will provide a more complete picture of human B-cell ontogeny. Culture systems developed for ES cells-embryoid ....They aim to create insulin-secreting B cells by identifying their progenitor cells and the moleculaes normally required for their development, in order to restore B-cell function in the people with type 1 diabetes. Mouse and human multipotent embryonic stem (ES) cells and fetal mouse panceas and adult pancreas duct cells will be used as sources of progenitor B cells. Comparative studies will provide a more complete picture of human B-cell ontogeny. Culture systems developed for ES cells-embryoid bodies (EB) - EB-derived cells, fetal pancreas and adult pancreas duct cells, will be employed to screen for and identify novel growth-differentiation factors and to optimise parameters for creating B cells in vitro or (re) generating B cells in vivo. Genetic constructs allowing regulated expression of fluorescently-tagged marker genes and growth-transcription factors will be introduced into cultured cells or transgenic mice to enable progenitor B cells to be tracked and isolated. Progenitor B cells will be typed with panels of known novel markers molecules at the gene and protein level, and gene expression profiles of tissue yielding B cells will be analysed across time to reveal further candidate markers. Molecules and methods effective in mouse systems will be applied to human ES cell-derived or pancreatic duct cells. The capacity to progenitor cells or insulin-secreting cells to ameliorate diabetes when transplanted into the testis, under the kidney capsule or into the pancreas of mouse models would represent proof-of-concept. Functional B cells derived from human ERS cells or pancreas duct cells, or growth factors that regenerate B cells in vivo, could together with appropriate immunotherapy restore B-cell function in people with type 1 diabetes.Read moreRead less
Enhancing Australia's Pandemic Influenza Vaccine Output By Increasing The Yeild Of Vaccine From Eggs
Funder
National Health and Medical Research Council
Funding Amount
$251,517.00
Summary
Influenza epidemics cause significant morbidity and mortality, particularly amongst the young and elderly. Unlike other vaccines, a new flu vaccine formulation needs to be prepared each year from the currently circulating strain. This involves a long process of preparing new seed vaccine stock, which is then tested, manufactured and distributed. The situation is even more complicated by the ability of different influenza strains to reassort with others. An example of current major concern is the ....Influenza epidemics cause significant morbidity and mortality, particularly amongst the young and elderly. Unlike other vaccines, a new flu vaccine formulation needs to be prepared each year from the currently circulating strain. This involves a long process of preparing new seed vaccine stock, which is then tested, manufactured and distributed. The situation is even more complicated by the ability of different influenza strains to reassort with others. An example of current major concern is the possibility of deadly avian flu viruses, such as H5N1, to gain the capacity to directly infect humans by recombining with a human strain and thereby starting a new global pandemic. When the next influenza pandemic occurs, the availability of a vaccine will be of the highest priority and early supply of vaccines will save millions of lives. Since vaccination is the only sustainable defense, we face an urgent need to have the capacity to supply large numbers of vaccine doses of influenza vaccines within a short period of time. Currently, the only way of producing flu vaccines is in eggs. The speed of vaccine supply is totally dependant on the yield of vaccine from eggs and the number of eggs that can be processed at any one time. Since there are severe constraints on the number of eggs that can be simultaneously processed, the limiting factor that can be addressed is the actual yield of vaccine per egg. The aim of this project is the develop methods that allow higher levels of vaccine virus to grow in eggs. We will take a multi-pronged approach to enhancing influenza vaccine production that are directed toward increasing the capacity of eggs to promote virus replication, as well as towards the vaccine strain to boost its ability to replicate in the egg. The outcome will be an enhanced capacity for vaccine manufacturers to quickly and effectively expand vaccine supplies which will directly impact on global morbidity and mortality during a flu pandemic.Read moreRead less
Examining A Core Assumption Of Policy And Services For Older Indigenous Australians
Funder
National Health and Medical Research Council
Funding Amount
$133,387.00
Summary
In aged care service planning, the age 50 years or over is used for the Indigenous Australian population in the same way as the age 70 years is used for the non-Indigenous population. This is based on the lower life expectancy of the Indigenous population which is presumed to result in a need for aged care services at younger ages. The underlying assumption is that Australia's Indigenous population aged over 50 has the same set of age-associated conditions and care needs as the non-Indigenous po ....In aged care service planning, the age 50 years or over is used for the Indigenous Australian population in the same way as the age 70 years is used for the non-Indigenous population. This is based on the lower life expectancy of the Indigenous population which is presumed to result in a need for aged care services at younger ages. The underlying assumption is that Australia's Indigenous population aged over 50 has the same set of age-associated conditions and care needs as the non-Indigenous population aged over 70. The evidence for this assumption is not established. It is well documented that the Indigenous population has worse health outcomes across all age groups relative to non-Indigenous Australians. However, our understanding of the details of the observed pattern is far from complete. This project seeks to compare the health status of the Indigenous population aged 50 years or over to the health status of the non-Indigenous population aged 70 years or over. The project will analyse a number of data sets to inform future directions in policy and service provision. A better understanding of these issues is fundamental to informed planning and allocation of resources, to identification of areas amenable to prevention strategies and to the development of approaches to care that meet the needs of Indigenous people.Read moreRead less